Compare · SLNO vs STEX
SLNO vs STEX
Side-by-side comparison of Soleno Therapeutics Inc. (SLNO) and Streamex Corp. (STEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLNO and STEX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 55.2x STEX ($50.1M).
- Over the past year, SLNO is down 22.0% and STEX is down 92.8% - SLNO leads by 70.8 points.
- STEX has hit the wire 11 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 1 for STEX).
- Company
- Soleno Therapeutics Inc.
- Streamex Corp.
- Price
- $53.02+0.08%
- $0.41-5.38%
- Market cap
- $2.76B
- $50.1M
- 1M return
- +0.76%
- -33.96%
- 1Y return
- -22.02%
- -92.80%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 11
- Recent ratings
- 12
- 1
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest STEX
- Streamex Corp Announces GLDY Now Available for Custody by CNB Custody - a Division of Community National Bank, Further Expanding Custody Options for GLDY
- SEC Form 8-K filed by Streamex Corp.
- SEC Form 4 filed by Streamex Corp.
- SEC Form 4 filed by Streamex Corp.
- Streamex Corp. to Present at the ThinkEquity Conference on October 15, 2026
- Streamex CEO Henry McPhie to Embark on Asia Tour with Events in Singapore and Hong Kong
- Streamex Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Streamex Co-Founder Morgan Lekstrom to Transition to Independent Director
- Streamex Corp. Announces Institutional Investment into Strategy Built Around GLDY
- Streamex Corp. to Participate in the Lytham Partners Fall 2026 Investor Conference